Clinical and densitometric efficacy of the association of interferon alpha and pamidronate in the treatment of osteoporosis in patients with systemic mastocytosis

Clinical Rheumatology

Volumn 26, Issue 2, 2007, Pages 242-243

  Laroche, M ^a   Bret, J ^a   Brouchet, A ^a   Mazieres B ^a  

^a CHU RANGUEIL   (France)

Author keywords

Interferon; Mastocytosis; Osteoporosis; Pamidronate

Indexed keywords

ALPHA INTERFERON; DEOXYPYRIDINOLINE; OSTEOCALCIN; PAMIDRONIC ACID;

ADULT; AGED; ARTICLE; BONE DENSITOMETRY; BONE DENSITY; BONE MARROW BIOPSY; BONE TURNOVER; CASE REPORT; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; COMORBIDITY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG WITHDRAWAL; EOSINOPHILIA; FEMALE; FEMUR NECK; FLU LIKE SYNDROME; FLUSHING; FOLLOW UP; HEPATOMEGALY; HUMAN; LYMPHADENOPATHY; MALE; MAST CELL; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN URINE LEVEL; SPINE; SYSTEMIC MASTOCYTOSIS; TREATMENT DURATION; URTICARIA PIGMENTOSA; VERTEBRA FRACTURE;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL RESPONSE MODIFIERS; BONE DENSITY; BONE MARROW CELLS; BONE REMODELING; DIPHOSPHONATES; DRUG THERAPY, COMBINATION; FEMALE; FEMUR NECK; HUMANS; INTERFERON-ALPHA; MALE; MASTOCYTOSIS, SYSTEMIC; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; SPINAL FRACTURES; SPINE; TREATMENT OUTCOME;

EID: 33845904625     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-006-0369-0     Document Type: Article

References (14)

1. Valent P et al (2003) Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol 122(5):695-717
2. Metcalfe DD, Akin C (2001) Mastocytosis: Molecular mechanisms and clinical disease heterogeneity. Leuk Res 25(7):577-582
3. Grardel B, Hardouin P (1992) Mastocytosis and bone manifestations. Results of the survey of the bone and phosphorus-calcium metabolism section of the French Society of Rheumatology. Rev Rhum Mal Osteoartic 59(1):57-63
4. Chines A et al (1993) Systemic mastocytosis and osteoporosis. Osteoporos Int 3(Suppl 1):147
5. De Gennes C, Kuntz D, de Vernejoul MC (1992) Bone mastocytosis. A report of nine cases with a bone histomorphometric study. Clin Orthop (279):281-291
6. Kluin-Nelemans HC et al (2003) Cladribine therapy for systemic mastocytosis. Blood 102(13):4270-4276
7. Pardanani A et al (2003) Imatinib for systemic mast-cell disease. Lancet 362(9383):535-536
8. Simon J et al (2004) Interest of interferon alpha in systemic mastocytosis. The French experience and review of the literature. Pathol Biol (Paris) 52(5):294-299
9. Brunel V et al (1998) Interferon alpha and pamidronate: A useful combination in the treatment of osteoporosis and systemic mastocytosis. Presse Med 27(2):64
10. Weide R et al (1996) Successful treatment of osteoporosis in systemic mastocytosis with interferon alpha-2b. Ann Hematol 72(1):41-43
11. Marshall A, Kavanagh RT, Crisp AJ (1997) The effect of pamidronate on lumbar spine bone density and pain in osteoporosis secondary to systemic mastocytosis. Br J Rheumatol 36(3):393-396
12. Brumsen C, Hamdy NA, Papapoulos SE (2002) Osteoporosis and bone marrow mastocytosis: Dissociation of skeletal responses and mast cell activity during long-term bisphosphonate therapy. J Bone Miner Res 17(4):567-569
13. Lehmann T et al (1996) Severe osteoporosis due to systemic mast cell disease: Successful treatment with interferon alpha-2B. Br J Rheumatol 35(9):898-900
14. Minne HW et al (2000) Pamidronate is effective in the treatment of osteoporosis in men due to systemic mastocytosis: A prospective, controlled study. Osteoporos Int 11(Suppl 2):S190 (abstract)